| Year |
Title |
Altmetric |
| 2023
|
Healthcare Access Domains Mediate Racial Disparities in Ovarian Cancer Treatment Quality in a US Patient Cohort: A Structural Equation Modelling Analysis..
Cancer Epidemiology, Biomarkers and Prevention.
32:74-81.
2023
|
|
| 2022
|
Development and Psychometric Evaluation of Healthcare Access Measures among Women with Ovarian Cancer.
Cancers.
14.
2022
|
|
| 2022
|
Identity-related experiences of Asian American trainees in gynecologic oncology.
Gynecologic Oncology Reports.
44.
2022
|
|
| 2022
|
Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.
Journal of Pain and Symptom Management.
64:537-545.
2022
|
|
| 2022
|
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study.
Journal of the National Comprehensive Cancer Network : JNCCN.
20:1255-1266E11.
2022
|
|
| 2022
|
Ineligible, Unaware, or Uninterested? Associations between Underrepresented Patient Populations and Retention in the Pathway to Cancer Clinical Trial Enrollment.
Jco Oncology Practice.
18:E1854-E1865.
2022
|
|
| 2022
|
Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
Gynecologic Oncology.
166:503-507.
2022
|
|
| 2022
|
Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
Gynecologic Oncology.
166:481-486.
2022
|
|
| 2022
|
Comparing financial hardship (FH) assessment tools among gynecologic cancer patients (491).
Gynecologic Oncology.
166:s243.
2022
|
|
| 2022
|
Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer.
Cancer Epidemiology, Biomarkers and Prevention.
31:1383-1393.
2022
|
|
| 2022
|
Piloting use of an out-of-pocket cost tracker among gynecologic cancer patients.
Gynecologic Oncology Reports.
41.
2022
|
|
| 2022
|
Effect of misoprostol on type 3 transformation zone of the cervix among Cameroonian women.
Gynecologic Oncology Reports.
40.
2022
|
|
| 2022
|
Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies.
Gynecologic Oncology.
165:11-13.
2022
|
|
| 2022
|
Misoprostol and estradiol to enhance visualization of the transformation zone during cervical cancer screening: An integrative review
2022
|
|
| 2022
|
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.
CA: A Cancer Journal for Clinicians.
2022
|
|
| 2021
|
Gynecologic oncology patients are ready for telemedicine in routine care: Results from a pre-COVID survey.
Gynecologic Oncology Reports.
38.
2021
|
|
| 2021
|
Ovarian Cancer Epidemiology, Healthcare Access and Disparities (ORCHiD): Methodology for a population-based study of black, Hispanic and white patients with ovarian cancer.
BMJ Open.
11.
2021
|
|
| 2021
|
Measuring Financial Distress and Quality of Life Over Time in Patients With Gynecologic Cancer-Making the Case to Screen Early in the Treatment Course.
Jco Oncology Practice.
17:e1576-e1583.
2021
|
|
| 2021
|
The oncology care model and the future of alternative payment models: A gynecologic oncology perspective..
Gynecologic Oncology.
162:529-531.
2021
|
|
| 2021
|
Evaluating Meaningful Levels of Financial Toxicity in Gynecologic Cancers.
Obstetrical and Gynecological Survey.
76:474-476.
2021
|
|
| 2021
|
Pathology findings among women with alterations in uterine bleeding patterns in cameroon.
Gynecologic Oncology Reports.
37.
2021
|
|
| 2021
|
Evaluating meaningful levels of financial toxicity in gynecologic cancers.
International Journal of Gynecological Cancer.
31:801-806.
2021
|
|
| 2021
|
Type 3 Transformation Zone of the Cervix and Risk of Missed Lesions during Cervical Cancer Screening with Visual Methods: A Case Report from Cameroon
2021
|
|
| 2021
|
The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?.
Gynecologic Oncology.
160:800-804.
2021
|
|
| 2021
|
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Gynecologic Oncology.
160:793-799.
2021
|
|
| 2020
|
Interventions targeting work-related concerns and linkage to appropriate financial resources are needed for gynecologic cancer patients starting a new line of treatment.
Gynecologic Oncology.
159:250.
2020
|
|
| 2020
|
Moderate/severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
Gynecologic Oncology.
159:311.
2020
|
|
| 2020
|
How, when, and with whom should cost of care conversations occur? preferences of two distinct cancer survivor groups.
Jco Oncology Practice.
16:E912-E921.
2020
|
|
| 2020
|
Moderate/Severe Distress in Half of Ovarian Cancer Patients Undergoing Treatment Highlights a Need for More Proactive Symptom and Psychosocial Management.
Gynecologic Oncology.
158:e11.
2020
|
|
| 2020
|
Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models.
Gynecologic Oncology.
156:701-709.
2020
|
|
| 2020
|
Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.
Gynecologic Oncology.
156:271-277.
2020
|
|
| 2019
|
Evaluating uptake and patient satisfaction with an out-of-pocket cost tracker for gynecologic cancer patients undergoing treatment..
Journal of Clinical Oncology.
37:101-101.
2019
|
|
| 2019
|
Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
International Journal of Gynecological Cancer.
29:1156-1163.
2019
|
|
| 2019
|
Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012)).
Gynecologic Oncology.
154:449.
2019
|
|
| 2019
|
The cost of treatment: Financial toxicity and opportunity costs among gynecologic cancer patients starting a new line of treatment.
Gynecologic Oncology.
154:6.
2019
|
|
| 2019
|
Perspectives on conversations about costs of cancer care of breast cancer survivors and cancer center staff: A qualitative study.
ACP journal club.
170:S54-S61.
2019
|
|
| 2019
|
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Gynecologic Oncology.
152:445-451.
2019
|
|
| 2019
|
Emerging From the Haze: A Pilot Study Evaluating Feasibility of a Psychoeducational Intervention to Improve Cancer-Related Cognitive Impairment in Gynecologic Cancer Survivors..
Journal of Palliative Care.
34:32-37.
2019
|
|
| 2019
|
Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer
2019
|
|
| 2018
|
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center..
Gynecologic Oncology.
151:501-505.
2018
|
|
| 2018
|
Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.
Gynecologic Oncology.
151:6-9.
2018
|
|
| 2018
|
Financial toxicity – An overlooked side effect.
Gynecologic Oncology.
150:3-6.
2018
|
|
| 2018
|
Bevacizumab, TKI, or PARPi? A targeted approach using composite value-based endpoints and biomarkers to individualize care for platinum-sensitive recurrent ovarian cancer (PSROC).
Gynecologic Oncology.
149:10-11.
2018
|
|
| 2018
|
Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP)..
Gynecologic Oncology.
149:232-240.
2018
|
|
| 2018
|
Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
Journal of Genetic Counseling.
27:177-186.
2018
|
|
| 2017
|
ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer..
Jco Oncology Practice.
13:e1030-e1039.
2017
|
|
| 2017
|
Prospective patient-elicited value assessments of options in the primary treatment of ovarian cancer.
Gynecologic Oncology.
145:45-46.
2017
|
|
| 2017
|
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated comprehensive cancer center.
Gynecologic Oncology.
145:152-153.
2017
|
|
| 2016
|
Antibiotic Use Negatively Influences Survival in Epithelial Ovarian Cancer: A Case for Studying the Microbiome.
Gynecologic Oncology.
143:204.
2016
|
|
| 2016
|
Genetic Counseling and Testing in Ovarian Cancer From the Patient Perspective.
Gynecologic Oncology.
143:220.
2016
|
|
| 2016
|
Glasgow Prognostic Score Associated with Lower Rates of R0 Cytoreduction in Women with Stage III Serous Ovarian Cancer.
Gynecologic Oncology.
143:219.
2016
|
|
| 2016
|
Antibiotics and the commensal microbiota: Impact on survival in women with epithelial ovarian cancer.
Gynecologic Oncology.
141:61.
2016
|
|
| 2016
|
Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer.
Gynecologic Oncology.
141:148-149.
2016
|
|
| 2016
|
Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer..
Journal of Clinical Oncology.
34:6630-6630.
2016
|
|
| 2015
|
Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications..
International Journal of Gynecological Cancer.
25:1271-1276.
2015
|
|
| 2015
|
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center..
Gynecologic Oncology.
138:689-693.
2015
|
|
| 2015
|
Setting the bar: Compliance with ovarian cancer quality indicators at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center (CCC).
Gynecologic Oncology.
137:41-42.
2015
|
|
| 2015
|
Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer..
Journal of Minimally Invasive Gynecology.
22:583-589.
2015
|
|
| 2014
|
Risk of complications after robotic hysterectomy for endometrial cancer in obese patients with preoperative comorbidities.
Gynecologic Oncology.
133:157.
2014
|
|
| 2014
|
Training the next generation of robotic surgeons using guided mentorship: a randomized controlled trial..
Journal of Minimally Invasive Gynecology.
21:1075-1079.
2014
|
|
| 2013
|
Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care..
Gynecologic Oncology.
131:508-511.
2013
|
|
| 2013
|
Reducing readmissions after robotic surgical management of endometrial cancer: A potential for improved quality care.
Gynecologic Oncology.
131:272-273.
2013
|
|
| 2011
|
Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment..
Journal of Controlled Release.
151:239-245.
2011
|
|
| 2008
|
Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature..
World Journal of Surgical Oncology.
6:117.
2008
|
|
| 2008
|
Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy..
World Journal of Surgical Oncology.
6:79.
2008
|
|
| 2007
|
Current immunotherapeutic strategies in breast cancer..
Surgical Oncology Clinics of North America.
16:841-ix.
2007
|
|
| 2006
|
High-Temperature Thermosetting Polyimide Nanocomposites Prepared with Reduced Charge Organoclay.
High Performance Polymers.
18:71-82.
2006
|
|
